After Jun 13, 2018’s trading in Acorda Therapeutics (ACOR) the algorithms behind ... Technical indicators for the stock have been bearish recently and support and resistance have been in the area of $30.82 and $32.72, respectively.
Accor SA is publicly listed on the Euronext Paris Stock Exchange (ISIN code: FR0000120404) and on the OTC Market …
Accor’s investors certainly don’t like it. The stock fell about 6 percent on Monday, obliterating about 860 million euros of equity value. That’s all the more …
OpinionBloomberg L.P.17d
One stock that fits that bill is Acorda Therapeutics (ACOR), which saw a welcome …
A covered call identified by MarketIntelligececenter.com's patented algorithm on Acorda Therapeutics (ACOR) could yield about 10.81% (30.84% annualized, for comparison purposes only) in 128 days. Pair a long position in the stock with …
Acorda Therapeutics, Inc. ACOR reported adjusted earnings of 14 cents per share ... Shares of Acorda slipped more than 1% following its earnings release. However, the stock has surged 45% in a year’s time versus the industry’s 13.5% …
Its lead drug candidate, CVT-301, shows strong potential. The company stock is priced attractively after a sudden slump in its value. Acorda Therapeutics Inc. (NASDAQ:ACOR) stock shows a strong recovery from its April slump, which erased …
UBS kept a "buy" rating on Accor shares, while Bernstein has an "underperform" rating on the stock. Previous acquisitions under Bazin, who took over in 2013, include Toronto-based Fairmont Raffles Hotels International, owner of London's …
Recently, the stock has been gaining momentum on takeover speculation. Acorda has upside from current levels based just on Inbrija’s potential. Last Friday, Acorda Therapeutics (ACOR) surged nearly 9% amid reports that the company …